Brief: Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant
12/12/2021 10:59
Dec 12 (Reuters) - Brii Biosciences Ltd 2137.HK :
* BRII BIO ANNOUNCES AMUBARVIMAB/ROMLUSEVIMAB COMBINATION
RETAINS
NEUTRALIZING ACTIVITY AGAINST OMICRON SARS-COV-2 VARIANT
* TESTS AGAINST OMICRON PSEUDOVIRUS SHOW COMBINATION RETAINS
NEUTRALIZING ACTIVITY AGAINST OMICRON,OTHER VARIANTS LIKE
DELTA,DELTA PLUS
* U.S. FDA EMERGENCY USE AUTHORIZATION REVIEW FOR
AMUBARVIMAB/ROMLUSEVIMAB COMBINATION IS UNDERWAY
Source text for Eikon: ID:nPn1SvfFKa
Further company coverage: 2137.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR